Lumenis makes Ofer an offer

Article

Lumenis has appointed Dov Ofer as its new designated Chief Executive Officer.

Lumenis has appointed Dov Ofer as its new designated Chief Executive Officer.

Dov Ofer, currently corporate vice president and general manager of HP-Scitex, holds an MBA degree from UC Berkeley, USA. His previous roles include President CEO of Scitex Vision and Manager of Matan Digital Printing.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
UVC light can be used as a noninvasive treatment for microbial keratitis. Image courtesy of Photon Therapeutics. Concept image for cornea treatment with ultraviolet light.

The future of microbial keratitis treatment is bright

Priyanka Mandal, MBChB FRCOphth;Sunil Shah, MBBS, FRCS(Ed), FRCOphth, FBCLA, FWCRS
April 29th 2025
Article

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A woman in a surgical mask, covering her nose and mouth, rubs her eyes. Concept image for autoimmune disease correlation to dry eye disease. Image credit: ©Prostock-studio – stock.adobe.com

Diagnosing types of dry eye in patients with autoimmune disease

Lynda Charters
April 24th 2025
Article

A young boy with glasses reading a book. Concept image for atropine drop paediatric myopia treatment approval in India. Image credit: ©WESTOCK – stock.adobe.com

ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)

Hattie Hayes;Emily Kaiser Maharjan;Jordana Joy
April 23rd 2025
Article

According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.

A red light with an alarm symbol. It reads "SOS." Concept image for emergency, medical emergency, neurology and ophthalmology referral. Image credit: ©Nicole Kwiatkowski – stock.adobe.com

Investigating causes of diplopia to minimise morbidity and mortality

Lynda Charters
April 23rd 2025
Article

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions

A photo of a boardroom with a presenter's projector screen, and easel, and many chairs. Concept image for Beth Marsh appointed CCO chief commercial officer of Neurotech Pharmaceuticals, ophthalmic industry news update. Image credit: ©nnpp's Images – canva.com

Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch

Kassi Filkins
April 22nd 2025
Article

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

© 2025 MJH Life Sciences

All rights reserved.